Allelic imbalance and biochemical outcome after radical prostatectomy.
OBJECTIVE
To compare the incidence of allelic imbalance (AI) in men with rapid disease progression with those who remained disease free after radical prostatectomy, with the aim of identifying genetic markers to predict prognosis and guide further treatment.


METHODS
Tumour and normal DNA were extracted from two matched groups of 31 men with extracapsular node-negative (pT3N0) prostate cancer who had undergone radical prostatectomy. One group comprised men who developed biochemical recurrence within 2 years of surgery and one group were prostate-specific antigen (PSA) free for at least 3 years. Men were matched for Gleason grade, preoperative PSA and pathological stage. Analysis was performed by genotyping.


RESULTS
Allelic imbalance was analysed using 30 markers, and was seen in at least one marker in 57 (92%) of the cases. Deletion at marker D10S211 (10p12.1) was significantly more common in the relapse group than the non-relapse group (35 vs 5%, P=0.03).


CONCLUSIONS
This study demonstrates significant association between AI on chromosome 10 and biochemical progression after radical prostatectomy.
Prostate Cancer Research Centre, Institute of Urology, London, UK. simonrjbott@hotmail.com
S R J
SR
Bott
J R W
JR
Masters
M C
MC
Parkinson
R S
RS
Kirby
M
M
Feneley
J
J
Hooper
M
M
Williamson
D000328:Adult; D000368:Aged; D022981:Allelic Imbalance / Q000235:genetics*; D014408:Biomarkers, Tumor / Q000032:analysis / Q000378:metabolism; D016022:Case-Control Studies; D002879:Chromosomes, Human, Pair 10; D004273:DNA, Neoplasm / Q000032:analysis; D018450:Disease Progression; D006801:Humans; D008297:Male; D018895:Microsatellite Repeats / Q000235:genetics*; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000235:genetics* / Q000401:mortality / Q000473:pathology; D009367:Neoplasm Staging; D011237:Predictive Value of Tests; D011336:Probability; D011379:Prognosis; D017430:Prostate-Specific Antigen / Q000097:blood; D011468:Prostatectomy / Q000009:adverse effects / Q000379:methods*; D011471:Prostatic Neoplasms / Q000401:mortality / Q000473:pathology / Q000601:surgery*; D012016:Reference Values; D020133:Reverse Transcriptase Polymerase Chain Reaction; D012494:Sampling Studies; D012680:Sensitivity and Specificity; D015996:Survival Rate
D014408:Biomarkers, Tumor; D004273:DNA, Neoplasm; D017430:Prostate-Specific Antigen